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Abstract: Background: Trans-arterial radioembolization (TARE) has shown promising results in
treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological
complete response (CR) in patients with intrahepatic HCC who were treated with TARE. Methods:
Patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited. CR was
defined according to the modified Response Evaluation Criteria in Solid Tumors. Cox regression
analysis was used to determine independent predictors of CR. Results: The median age of study
participants (83 men and 19 women) was 64.3 years. The mean survival after TARE was 55.5 months,
and 21 (20.6%) patients died during the study period. Patients who achieved CR (14 patients, 13.7%)
had significantly higher serum albumin level (median 4.1 vs. 3.9 g/dL), lower total bilirubin level
(median 0.6 vs. 0.7 mg/dL), lower aspartate aminotransferase level (median 30.0 vs. 43.0 IU/L),
lower alkaline phosphatase level (median 79.0 vs. 103.0 IU/L), lower alpha-fetoprotein level (median
12.7 vs. 39.9 ng/mL), lower des-gamma-carboxyprothrombin level (median 575.5 vs. 2772.0 mAU/mL),
lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0), and smaller maximal
tumor diameter (median 6.3 vs. 9.0 cm) compared to those who did not achieve CR (all p < 0.005).
Multivariate Cox regression analysis showed that lower MELD score (hazard ratio (HR) = 0.436,
p = 0.015) and maximal tumor size < 9 cm (HR = 11.180, p = 0.020) were independent predictors of
an increased probability of radiological CR after TARE. Conclusions: Low MELD score and small
maximal tumor size were independently associated with an increased probability of CR after TARE
in patients with intrahepatic HCC.
Keywords: hepatocellular carcinoma; trans-arterial radioembolization; radioembolization; complete
response; outcome; predictor
1. Introduction
Hepatocellular carcinoma (HCC) is one of the well-known leading causes of cancer-related deaths
worldwide [1]. Despite the improvements in surveillance protocols, which have increased the diagnosis
of early HCC [2,3], a considerable proportion of patients with intrahepatic HCC are not considered
candidates for curative treatments such as local ablation, surgical resection, and liver transplantation,
for reasons such as decreased liver function, large tumor burden, and vascular invasion [4–6].
Although conventional trans-arterial chemoembolization (TACE) is widely used for the treatment
of HCC in the intermediate and advanced stages, the procedure has limited application due to the
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risk of procedure-related liver failure and complications, especially in patients of old age with large
tumor or portal vein invasion [7]. Therefore, trans-arterial radioembolization (TARE), which involves
intra-arterial injection of radioactive substances such as yittrium-90 (90Y)-loaded microspheres and
minimally modifies hepatic arterial flow (compared to TACE), can be a safe alternative treatment for
patients with post-TACE risks [8–10]. In addition, several previous studies have shown favorable
outcomes, including significantly longer time to progression, better local tumor control, and higher
quality of life, after TARE than after TACE [10–14].
TARE generally shows a delayed response in imaging studies, with confounding from true
responses (e.g., post-treatment inflammation, transient increase in lesion size associated with
successful necrosis, peritumoral changes, and hemorrhage in the necrotic tumor) in some cases [15–18].
Although favorable response based on arterial enhancement criteria, such as the modified Response
Evaluation Criteria in Solid Tumors (mRECIST), predicts good prognostic outcomes for several HCC
therapies [19–23], whether such enhancement criteria are suitable for the response evaluation of HCC
treated with TARE has not been fully validated. Moreover, recent studies have shown that achieving
complete response (CR) after TARE based on the enhancement criteria can mean a real complete cure;
and even if does not, TARE can serve as a bridging therapy for other curative options [17,24]. However,
the predictors of favorable response in patients treated with TARE still remain not well-known.
In this study, we aimed to identify the independent predictors of mRECIST-based CR in patients




We retrospectively reviewed the medical records of patients with HCC who were treated with
TARE at Severance Hospital, Yonsei University College of Medicine between 2011 and 2017.
Exclusion criteria were as follows: (1) age < 19 years; (2) Eastern Cooperative Oncology Group
performance status score > 2; (3) presence of extrahepatic HCC; (4) presence of ascites; (5) significant
extrahepatic disease representing an imminent life-threatening outcome; (6) uncontrolled medical
comorbidities; (7) mortality of unknown cause that was not due to illness; (8) mortality that was
absolutely due to procedure-related complications; (9) follow-up loss or death within 3 months after
TARE treatment; (10) other treatment modalities such as TACE, intra-arterial chemotherapy, and
surgical resection within 6 months after TARE treatment, or excessively high Lipiodol uptake due to
previous TACE treatment that confounded response evaluation.
The study protocol was in accordance with the 1975 Declaration of Helsinki guidelines. Due to
the retrospective nature of this study, the need for written informed consent was waived. The study
protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of
Severance Hospital.
2.2. Diagnosis and Staging
HCC was diagnosed histo-pathologically or clinically, according to the guidelines proposed
by the Korea Liver Cancer Study group. The typical imaging hallmarks of HCC on dynamic
computed tomography (CT) or magnetic resonance imaging (MRI) were described as arterial phase
hyper-enhancement with washout in the portal venous, delayed, or hepatobiliary phases [25].
2.3. Yttrium-90 Radioembolization
A pre-delivery angiographic mapping procedure (i.e., angiography with technetium-99
macro-aggregated albumin scanning) was performed to evaluate the hepatic artery, enteric collaterals
within the anticipated arterial treatment zone, and hepatopulmonary shunt. TARE was performed
with resin (SIR-Spheres®; Sirtex Medical, Sydney, Australia) or glass particles (TheraSphere®;
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Biocompatibles UK Ltd., Surrey, UK) loaded with 90Y. The dose was determined based on the
planning angiogram and prepared in the nuclear medicine department, according to the preparation
guideline provided by the manufacturer. The target absorbed radiation doses to the normal liver
and lungs should not exceed 70 and 25 Gy, respectively. The entire process of TARE was conducted
according to previous guidelines [26].
2.4. Assessment of Treatment Responses Using mRECIST
The treatment responses were assessed at 1,3, and 5–6 months after TARE sessions, using liver
dynamic CT or MRI with physical examination and blood tests. Thereafter, treatment responses were
further assessed at intervals of 2–3 months. Two independent radiologists analyzed the images to
minimize the possibility of false categorization.
Modified RECIST was used for response evaluation. For target lesions, tumor response was
defined as a CR, indicated by the complete disappearance of viable lesions, or a radiological partial
response (PR), defined as a 30% decrease from baseline. Radiological progressive disease (PD) was
defined as a 20% increase from baseline or the presence of newly developed lesions. Radiological
stable disease (SD) was defined as an increase/decrease of the percentage between PD and PR [19].
In addition to CR, PR, SD, and PR, the “best response” was defined as the most favorable response
during 6 months after TARE.
2.5. Statistical Analysis
Patient characteristics were summarized by mean ± SD, median and range of continuous variables,
and percentages for categorical variables. To compare quantitative variables, Student’s t-test or
Mann-Whitney test was used. Chi-square test or Fisher’s exact test was used to compare qualitative
variables. ROC analyses were used to dichotomize several continuous variables. For example, we
used the rounded cutoff value 9 cm for tumor size based on the calculated cutoff value of 9.1 cm
(sensitivity 52.4% and specificity 67.9%), and MELD score of 6 points based on the calculated cutoff
value of 6.5 points (sensitivity 85.7% and specificity 34.6%), which maximized the sum of sensitivity
and specificity.
Overall survival (OS) was estimated using Kaplan-Meier analysis. OS was defined as the time
interval between the date of TARE and death, or to the last follow-up date for patients who were
still alive at the time of analysis. Survival curves were compared using the log-rank test. The
event of interest was CR: univariate analysis was performed for all of the variables in this study,
and then multivariable analysis using the Cox proportional hazards model was used to explore the
independent predictors.
A p < 0.05 was considered statistically significant, with a confidence interval (CI) of 95%. All
statistical analyses were performed using the IBM SPSS Statistics software package version 23.0.0.0.
(IBM SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Patient Characteristics
The flow of study population selection is described in Figure 1. A total of 146 patients treated
with TARE for intrahepatic HCC were recruited. After excluding 44 patients who met our exclusion
criteria, 102 patients were finally selected for our study.
The baseline characteristics of the study population (83 (81.4%) men and 19 (18.6%) women) at the
time of TARE are shown in Table 1. The median patient age was 64.3 years. Sixty-one (55.5%) patients
had liver cirrhosis and 71 (69.6%) patients had viral hepatitis. All patients had an Eastern Cooperative
Oncology Group performance status score of 0 or 1.
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Figure 1. Flow of the study population selection. HCC, hepatocellular carcinoma; TARE, trans-arterial 
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Table 1. Baseline characteristics of the study population (n = 102). 
Variables Values 
Age 64.3 (53.6–72.8) 
Male sex 83 (81.4) 
Body mass index, kg/m2 23.9 (21.3–25.8) 
Diabetes mellitus 44 (43.1) 
Hypertension 59 (57.8) 
Liver cirrhosis 61 (55.5) 
Viral etiology 71 (69.6) 
Heavy alcoholics 6 (5.9) 
Platelet count, 109/L 198.5 (121.3–261.5) 
Total bilirubin, mg/dL 0.6 (0.5–0.9) 
Serum albumin, g/dL 3.9 (3.5–4.1) 
Aspartate aminotransferase, IU/L 40.0 (28.8–64.3) 
Alanine aminotransferase, IU/L 28.5 (18.0–45.0) 
Alkaline phosphatase, IU/L 95.5 (76.0–138.5) 
Prothrombin time, INR 1.0 (0.96–1.10) 
AFP, ng/mL 37.1 (5.0–2590.1) 
Figure 1. Flow of the study population selection. HCC, hepatocellular carcinoma; TARE, trans-arterial
radioembolization; TACE, trans-arterial chemoembolization; ECOG, Eastern Cooperative Oncology Group.
The median alpha-fetoprotein level was 37.1 ng/mL. The median des-gamma-carboxyprothrombin
level was 1780.0 mAU/mL. An infiltrative tumor pattern was identified in 20 (19.6%) patients. The
median diameter of the large t measurable lesi n was 8.3 cm. Thirty-six (35.3%) patients had multiple
tumors, of whom 26 (25.5%) had more than three tumors. Seventy-four (72.5%) patients had uni-lobar
tumors, whereas 28 (27.5%) had bi-lobar tumors. Tumor invasion to peripheral branches of the portal
vein was identified in 19 (18.6%) patients, of whom eight (7.8%) had portal vein tumor invasion to the
first-order branch. Hepatic vein invasion was identified in five (4.9%) patients.
3.2. Treatment Outcomes after TARE
During the follow-up period (mean 27.1, median 20.7 months), 21 patients (20.6%) died. The
cumulative survival rate after TARE was 96.1% at 6 months, 89.3% at 12 months, and 81.7% at
24 months, respectively. (Figure 2A). As the best response, CR according to mRECIST was achieved in
14 (13.7%) patients, whereas PR, SD, and PD were achieved in 44 (43.1%), 41 (40.2%), and three (2.9%)
patients, respectively.
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Table 1. Baseline characteristics of the study population (n = 102).
Variables Values
Age 64.3 (53.6–72.8)
Male sex 83 (81.4)
Body mass index, kg/m2 23.9 (21.3–25.8)
Diabetes mellitus 44 (43.1)
Hypertension 59 (57.8)
Liver cirrhosis 61 (55.5)
Viral etiology 71 (69.6)
Heavy alcoholics 6 (5.9)
Platelet count, ×109/L 198.5 (121.3–261.5)
Total bilirubin, mg/dL 0.6 (0.5–0.9)
Serum albumin, g/dL 3.9 (3.5–4.1)
Aspartate aminotransferase, IU/L 40.0 (28.8–64.3)
Alanine aminotransferase, IU/L 28.5 (18.0–45.0)
Alkaline phosphatase, IU/L 95.5 (76.0–138.5)
Prothrombin time, INR 1.0 (0.96–1.10)
AFP, ng/mL 37.1 (5.0–2590.1)
DCP, mAU/mL 1780.0 (135.5–8119.5)
MELD score 7.6 (6–8)
ALBI grade
Grade 1/2/3 52 (51.0)/47 (46.1)/3 (2.9)
Tumor pattern
Nodular/infiltrative 82 (80.4)/20 (19.6)
Maximum tumor diameter, cm 8.3 (6.0–10.5)
Multiple tumors 36 (35.3)
Tumor burden >50% 10 (9.8)
Tumor distribution
Uni-lobar/bi-lobar 74 (72.5)/28 (27.5)
Portal vein thrombosis 19 (18.6)
First-/second-/segmental-order branch 8/6/5
Hepatic vein invasion 5 (4.9)
Variables are expressed as median (interquartile range) or n (%). INR, international normalized ratio;
AFP, alpha-fetoprotein; DCP, des-gamma-carboxyprothrombin; MELD, model for end-stage liver disease;
ALBI, albumin-bilirubin.
The cumulative survival rate of patients who achieved CR was statistically similar to that of
patients who achieved PR (p = 0.451 by log-rank test), whereas it was significantly higher than that of
patients who achieved SD (p = 0.048 by log-rank test) and PD (p < 0.001 by log-rank test) (Figure 2B).
The survival probabilities of the patients who achieved CR after TARE were 100%, 100%, and 88.9%
at 6, 12, and 24 months, respectively. Those of the patients who achieved PR after TARE were 100%,
97.1%, and 92.7% at 6, 12, and 24 months, respectively. Those of the patients who achieved SD after
TARE were 90.2%, 77.2%, and 62.7% at 6, 12, and 24 months, respectively. Those of the patients who
achieved PD after TARE were 66.7%, 33.3% and 0% at 6, 12, and 24 months, respectively.
During the follow-up period, among 14 patients who achieved CR, CR was maintained in five
patients without further treatments, whereas four patients underwent subsequent curative therapy
including liver resection (n = 3) and liver transplantation (n = 1). Four patients underwent subsequent
TACE at 7 or 8 months due to local recurrence, and one patient was subsequently treated with
intra-arterial infusional chemotherapy owing to early recurrence at 4 months.
3.3. Comparison between Patients with and without CR
Baseline characteristics were compared between patients who achieved CR (n = 14, 13.7%) and
those who did not (n = 88, 86.3%) (Table 2). Patients with CR had favorable baseline laboratory
characteristics, such as lower total bilirubin (median 0.6 vs. 0.8 mg/dL), higher serum albumin level
(median 4.1 vs. 3.9 g/dL), lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0),
and lower albumin-bilirubin (ALBI) gradient score (median −2.8 vs. −2.5) compared to patients who
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did not achieve CR (all p < 0.05). Moreover, patients who achieved CR had smaller maximum tumor
diameter (median 6.3 vs. 9.0 cm, p = 0.012). Other tumor characteristics were statistically similar
between the two groups (all p > 0.05).
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Figure 2. Kaplan-Meier analysis for overall survival of the entire study population (n = 102) (A) and
subgroups according to the best response (B). Kaplan-Meier curves for overall survival according
to tumor size (C) and MELD score (D), which were the identified predictors for complete response
achievement. mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete
response; PR, partial response; SD, stable disease; PD, progressive disease; MELD, model for end-stage
liver disease.
3.4. Predictors of CR
In univariate analysis, a higher serum albumin level (>4.1 g/dL), lower aspartate aminotransferase
level (<40 or <32 IU/L), lower alkaline phosphatase level, lower MELD score, lower ALBI score, and
smaller maximum tumor diameter (<9 cm) significantly predicted an increased probability of CR after
TARE (all p < 0.05) (Appendix A, Table A1).
Subsequent multivariate analysis based on significant variables in the univariate analysis revealed
that lower MELD score (HR = 0.436, 95% CI, 0.224–0.849; p = 0.015) and maximum tumor diameter < 9 cm
(HR = 11.180, 95% CI, 1.458–85.731; p = 0.020) independently predicted an increased probability of CR
after TARE (Table 3).
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Table 2. Comparison between patients who achieved complete response (CR) and those who did not.
Variables CR Group (n = 14,13.7%)
Non-CR Group (n = 88,
86.3%) p-Value
Age 62.0 (51.1–75.2) 64.6 (53.8–72.7) 0.993
Male sex 14 (100.0) 69 (78.4) 0.054
Body mass index, kg/m2 24.4 (22.0–26.9) 23.7 (21.3–25.6) 0.539
Diabetes mellitus 9 (64.3) 35 (39.8) 0.085
Hypertension 8 (57.1) 51 (58.0) 0.954
Liver cirrhosis 11 (78.6) 50 (56.8) 0.123
Viral etiology 11 (78.6) 60 (68.2) 0.432
Heavy alcoholics 2 (14.3) 4 (4.5) 0.150
Platelet count, ×109/L 160.0 (96.3–202.5) 204.0 (140.0–272.8) 0.056
Bilirubin, mg/dL 0.6 (0.5–0.7) 0.8 (0.5–1.0) 0.006
Albumin, g/dL 4.1 (3.8–4.3) 3.9 (3.5–4.1) 0.031
Aspartate aminotransferase, IU/L 30.0 (23.5–35.0) 43.0 (30.0–66.0) <0.001
Alanine aminotransferase, IU/L 24.0 (22.0–35.8) 31.0 (18.0–46.5) 0.057
Alkaline phosphatase, IU/L 79.0 (64.8–97.5) 103.0 (77.0–156.0) <0.001
Prothrombin time, INR 1.0 (1.0–1.1) 1.0 (1.0–1.1) 0.702
AFP, ng/mL 12.7 (3.1–284.9) 39.9 (5.2–3078.0) 0.001
DCP, mAU/mL 575.5 (33.0–2000.8) 2772.0 (5.2–3078.0) 0.003
MELD score 6.0 (6.0–7.0) 7.0 (6.0–8.0) <0.001
ALBI score −2.8 (−2.9 to −2.5) −2.5 (−2.8 to −2.2) 0.024
Grade 1/2/3 10 (71.4)/4 (28.6)/0 (0) 42 (47.7)/43 (48.9)/3(0.03) 0.099
Infiltrative tumor pattern 4 (28.6) 16 (18.2) 0.363
Maximum tumor diameter, cm 6.3 (5.2–8.3) 9.0 (6.4–11.4) 0.012
Multiple tumors 4 (28.6) 32 (36.4) 0.571
Tumor burden >50% 0 (0) 10 (11.4) -
Bi-lobar tumor distribution 1 (7.1) 27 (30.7) 0.067
Portal vein thrombosis 1 (7.1) 18 (20.5) 0.458
First-/second-/segmental-order
branch 0/0/1 8/6/4 -
Hepatic vein invasion 0 (0.0) 5 (5.7) -
Variables are expressed as median (interquartile range) or n (%). CR, complete response; INR, international
normalized ratio; AFP, alpha-fetoprotein; DCP, des-gamma-carboxyprothrombin; MELD, model for end-stage liver
disease; ALBI, albumin-bilirubin.
Cumulative survival rate of patients with maximum tumor diameter < 9 cm and those with MELD
score ≤ 6 was significantly longer than those of their counterparts (p = 0.100 and p = 0.022 by log-rank
test, respectively). The survival probabilities of patients with maximum tumor diameter < 9 cm vs.
≥ 9 after TARE were 96.5%, 90.6%, and 88.3% vs. 95.6%, 87.5%, and 76.8% at 6, 12, and 24 months,
respectively. In addition, the survival probabilities of the patients with MELD score ≤ 6 vs. > 6 after
TARE were 100%, 100%, and 95.8% vs. 94.4%, 84.7%, and 78.2% at 6, 12, and 24 months, respectively
(Figure 2C,D).
Table 3. Results of multivariate Cox regression analysis to identify predictors of complete response.
Variables
Univariate Multivariate Analysis
p-Value p-Value Hazards Ratio (95% CI)
Albumin, g/dL 0.036 0.588 3.685 (0.033–415.239)
ALBI score 0.028 0.859 1.548 (0.013–189.867)
AST <32 IU/L 0.016 0.361 1.846 (0.495–6.889)
ALP <90 IU/L 0.042 0.573 1.526 (0.351–6.629)
MELD score 0.018 0.015 0.436 (0.224–0.849)
Maximum tumor
diameter 9 cm 0.015 0.020 11.180 (1.458–85.731)
ALBI, albumin-bilirubin; AST, aspartate aminotransferase; ALP, alkaline phosphatase; MELD, model for end-stage
liver disease; CI, confidence interval.
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3.5. Pathological Correlation with Radiological CR
Pathological investigation was done in four patients in the CR group (Table 4). Total necrosis was
observed in two patients (one with a single tumor and the other with two tumors), and near-total
necrosis was noted in two patients (95% necrosis in the larger tumor and 20% necrosis in the smaller
tumor in one patient with two tumors, and 95% necrosis in the other patient with a single tumor).






















A 58 Male 6 1 6.0 17 Resection Total necrosis
B 58 Male 6 3 8.8 7 Resection Total necrosis















TARE, trans-arterial radioembolization; MELD, model for end-stage liver disease.
4. Discussion
It is important to determine whether the radiological response after locoregional treatment (LRT)
for HCC accurately reflects not only the shrinkage in tumor size but also the actual tumor viability.
Although the European Association for the Study of the Liver (EASL) criteria and mRECIST are
known to be suitable for assessing response and reflecting survival after TACE for HCC [19–23],
there is still controversy about which criteria correctly reflect survival after TARE, owing to some
confounders including delayed necrosis, peritumoral edema, rim enhancement with granulation tissue,
and hemorrhages in the necrotic tumor after TARE [15,27]. Several previous studies have argued
that the existing arterial enhancement criteria were not enough to evaluate the long-term prognosis
after TARE, and have suggested new response criteria using tumor density or response based on
positron emission tomography-CT or MRI to reflect the prognosis after TARE more accurately [28–30].
Nevertheless, recent studies have confirmed that CR achievement based on arterial enhancement
criteria well reflects the actual complete pathological necrosis (CPN) after LRT, including TARE [29,31].
Therefore, we attempted to identify the independent predictors of mRECIST-based CR in patients
with intrahepatic HCC who were treated with TARE.
To our knowledge, this is the first study to identify independent predictors of radiological CR
achievement after TARE for intrahepatic HCC. In the present study, 14 (13.7%) patients achieved
CR as the best response, in comparison to the previously reported rate (6–32%) of CR achievement
according to the enhancement criteria after TARE [11–13]. We also found that smaller maximal tumor
size (<9 cm) and lower MELD score independently predicted CR according to mRECIST, as the best
response for intrahepatic HCC. The OS of each response group was significantly different (57.5 months
in the CR group vs. 48.0 months in the SD group vs. 59.2 months in the PR group vs. 9.1 months
in the PD group; overall p < 0.001, log-rank test). Four of 14 patients in the CR group underwent
liver resection or liver transplantation, and showed near-total necrosis of the treated lesion, which
was appropriately correlated with the achievement of CR according to mRECIST. Recently, Labgaa
et al. reported that 32 of 349 patients (9%) treated with TARE for unresectable HCC could receive
curative treatments (22 patients with liver transplantation and 10 with resection); and among them,
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18 (56%) patients showed CR according to mRECIST [32]. The study indicated that it might be clinically
important to predict CR after TARE to guide the future treatment direction toward curative treatments
such as liver transplantation and resection, confirming the therapeutic role of TARE as a bridging or
down-staging therapy.
Similar to our study, previous studies have also demonstrated that a small tumor size is a good
predictor of tumor response and survival after LRTs [33–35] and is also related to CPN [29]. Recently,
Riaz et al. reported that CPN was frequently observed in the smaller HCC group treated with TARE
(89% of lesions with pretreatment size < 3 cm), and all 12 cases with CR according to the EASL criteria
showed perfect CPN [31]. These findings support our results indicating that a small tumor size is an
independent predictor of achieving CR according to mRECIST, and that pathological necrosis was well
correlated with the radiological response, despite the small number of cases with surgical pathology
confirmation. Interestingly, our study showed that relatively large tumors up to 9 cm in diameter
could be appropriately treated with TARE, resulting in near-total pathological necrosis, indicating that
patients with unresectable intrahepatic HCC might benefit from TARE, if well selected, despite having
a large tumor.
In addition, we found that a lower MELD score is another favorable predictor for achieving CR
after TARE. Since several studies have revealed that the MELD score might be useful as a general
prognostic indicator after TARE for HCC [28,36], our results might indicate that MELD score can be
used to predict the long-term outcome and probability of CR achievement. However, the association
between MELD score and radiological response after LRT is barely reported in the literature, and
further validation studies are required to confirm the exact reason for this association between MELD
score and the probability of CR achievement. Additionally, the cutoff for MELD score to significantly
discriminate different OS values was only 6. However, our results should be interpreted with caution,
as the MELD score of our study population was dichotomized for easier understanding, and our
proposed cutoff MELD score of 6 points might have been biased due to the skewed distribution of liver
function in our study population. Instead of proposing any specific cutoff value for MELD score, our
results might provide the rationale for selecting optimal candidates who may benefit from TARE based
on the baseline liver function.
This study had several limitations. First, since it was a retrospective study from a single Korean
center with associated selection bias, data might not be representative of real-world situations. In fact,
the OS of our study population (mean 55.5 months) seems relatively longer than that reported in other
studies on TARE (mean 36 months or median 10–17 months) [11–13,37]. Second, although we first tried
to identify the potential predictors of CR in univariate analysis and then used subsequent multivariate
analysis to identify independent predictors, the over-fitting in multivariate analysis using six variables,
compared to the extremely small number of events (only 14 events for CR), might have obviously
limited the strength of evidence in our study. Third, as most patients in our study had Child-Pugh
class A class liver function (n = 96, 94.1%) and hepatitis B-viral infection (n = 66 of 71 [92.9%] with viral
etiology), the influence of decreased liver function of Child-Pugh B class and hepatitis C viral infection
could not be assessed, which should be further investigated in larger sample studies in the future.
Fourth, we could not fully assess the association between radiological and pathological responses
due to the limited number of surgical cases. Further studies with patients who underwent surgical
resection or liver transplantation after TARE can resolve this issue.
5. Conclusions
In conclusion, lower MELD score and smaller maximal tumor size independently predicted an
increased probability of achieving CR after TARE in patients with unresectable intrahepatic HCC. Our
results might help physicians in selecting the optimal candidates who may benefit the most from TARE
based on the identified predictors of CR.
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Appendix A
Table A1. Univariate Cox-regression analysis to predict CR.
Variable
Univariate Analysis
p Value Hazards Ratio (95% CI)
Age > 65 years 0.735 0.821(0.263–2.564)
Male gender 0.998 -
Body mass index, kg/m2 0.535 1.052 (0.896–1.235)
Diabetes mellitus 0.094 2.726 (0.843–8.814)
Hypertension 0.954 0.967 (0.309–3.025)
Liver cirrhosis 0.135 2.787 (0.726–10.690)
Viral etiology 0.437 1.711 (0.442–6.621)
Heavy alcoholics 0.173 3.500 (0.577–21.215)
Platelet count, ×109/L 0.061 0.993 (0.986–1.000)
Total bilirubin, mg/dL 0.124 0.213 (0.030–1.530)
Serum albumin, g/dL 0.036 5.864 (1.121–30.672)
>4.1 g/dL 0.029 3.368 (1.129–10.052)
Aspartate aminotransferase, IU/L 0.014 0.937 (0.889–0.987)
<40 IU/L 0.021 11.016 (1.441–84.242)
<32 IU/L 0.016 4.292 (1.312–14.042)
Alanine aminotransferase, IU/L 0.220 0.978 (0.945–1.013)
Alkaline phosphatase, IU/L 0.037 0.979 (0.959–0.999)
Prothrombin time, INR 0.699 0.340 (0.001–80.476)
AFP, ng/mL 0.381 1.000 (1.000–1.000)
DCP, mAU/mL 0.226 1.000 (1.000–1.000)
MELD score 0.018 0.440 (0.223–0.871)
ALBI score 0.025 0.169 (0.035–0.801)
ALBI grade 2 (vs. grade 1) 0.149 0.426 (0.133–1.357)
Infiltrative tumor pattern 0.368 1.800 (0.501–6.473)
Maximum tumor diameter, cm 0.016 0.746 (0.588–0.946)
<9 cm 0.015 13.0 (1.630–103.687)
Multiple tumors 0.572 1.429 (0.414–4.928)
Bi-lobar tumor distribution 0.100 0.174 (0.022–1.396)
Portal vein thrombosis 0.260 0.299 (0.037–2.440)
CR, complete response; INR, international normalized ratio; AFP, alpha-fetoprotein; DCP, des-gamma-
carboxyprothrombin; MELD, model for end-stage liver disease; ALBI, Albumin-Bilirubin; CI, confidence interval.
Curr. Oncol. 2021, 28 975
References
1. McGlynn, K.A.; Petrick, J.L.; London, W.T. Global epidemiology of hepatocellular carcinoma: An emphasis
on demographic and regional variability. Clin. Liver Dis. 2015, 19, 223–238. [CrossRef] [PubMed]
2. Llovet, J.M.; Bruix, J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol.
2008, 48, S20–S37. [CrossRef]
3. Shin, H.; Jung, Y.W.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Han, K.H.; Kim, Y.Y.; Choi, J.Y.; Kim, S.U.
Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients
with chronic hepatitis B. Clin. Mol. Hepatol. 2019, 25, 390–399. [CrossRef]
4. Sotiropoulos, G.C.; Lang, H.; Frilling, A.; Molmenti, E.P.; Paul, A.; Nadalin, S.; Radtke, A.; Brokalaki, E.I.;
Saner, F.; Hilgard, P.; et al. Resectability of hepatocellular carcinoma: Evaluation of 333 consecutive cases at a
single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006, 53,
322–329. [PubMed]
5. Kim, J.Y.; Sinn, D.H.; Gwak, G.Y.; Choi, G.S.; Saleh, A.M.; Joh, J.W.; Cho, S.K.; Shin, S.W.; Carriere, K.C.;
Ahn, J.H.; et al. Trans-arterial chemoembolization versus resection for intermediate-stage (BCLC B)
hepatocellular carcinoma. Clin. Mol. Hepatol. 2016, 22, 250–258. [CrossRef]
6. Kim, S.U.; Kim, B.K.; Han, K.H. Clinical application of liver stiffness measurement using transient
elastography: A surgical perspective. Digestion 2013, 88, 258–265. [CrossRef]
7. Iwadou, S.; Nouso, K.; Kuwaki, K.; Kobayashi, Y.; Nakamura, S.; Tanaka, H.; Miyoshi, K.; Ohnishi, H.;
Miyake, Y.; Shiraha, H.; et al. Time-dependent analysis of predisposing factors for the recurrence of
hepatocellular carcinoma. Liver Int. 2009, 30, 1027–1032. [CrossRef] [PubMed]
8. Sangro, B.; Salem, R. Trans-arterial chemoembolization and radioembolization. Semin. Liver Dis. 2014, 34,
435–443. [CrossRef]
9. Kim, H.-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin. Mol. Hepatol. 2017, 23,
109–114. [CrossRef]
10. Kulik, L.M.; Carr, B.I.; Mulcahy, M.F.; Lewandowski, R.J.; Atassi, B.; Ryu, R.K.; Sato, K.T.; Benson, A., 3rd;
Nemcek, A.A., Jr.; Gates, V.L.; et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma
with and without portal vein thrombosis. Hepatology 2008, 47, 71–81. [CrossRef]
11. Hilgard, P.; Hamami, M.; Fouly, A.E.; Scherag, A.; Muller, S.; Ertle, J.; Heusner, T.; Cicinnati, V.R.; Paul, A.;
Bockisch, A.; et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:
European experience on safety and long-term survival. Hepatology 2010, 52, 1741–1749. [CrossRef] [PubMed]
12. Salem, R.; Lewandowski, R.J.; Mulcahy, M.F.; Riaz, A.; Ryu, R.K.; Ibrahim, S.; Atassi, B.; Baker, T.; Gates, V.;
Miller, F.H.; et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A
comprehensive report of long-term outcomes. Gastroenterology 2010, 138, 52–64. [CrossRef] [PubMed]
13. Sangro, B.; Carpanese, L.; Cianni, R.; Golfieri, R.; Gasparini, D.; Ezziddin, S.; Paprottka, P.M.; Fiore, F.; Van
Buskirk, M.; Bilbao, J.I.; et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular
carcinoma across barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011, 54, 868–878.
[CrossRef] [PubMed]
14. Lee, E.W.; Khan, S. Recent advances in trans-arterial embolotherapies in the treatment of hepatocellular
carcinoma. Clin. Mol. Hepatol. 2017, 23, 265–272. [CrossRef]
15. Bester, L.; Hobbins, P.G.; Wang, S.C.; Salem, R. Imaging characteristics following 90yttrium microsphere
treatment for unresectable liver cancer. J. Med. Imaging Radiat. Oncol. 2011, 55, 111–118. [CrossRef] [PubMed]
16. Semaan, S.; Makkar, J.; Lewis, S.; Chatterji, M.; Kim, E.; Taouli, B. Imaging of hepatocellular carcinoma
response after 90Y radioembolization. Am. J. Roentgenol. 2017, 209, W263–W276. [CrossRef]
17. Song, J.E.; Jung, K.S.; Kim, D.Y.; Song, K.; Won, J.Y.; Lee, H.W.; Kim, B.K.; Kim, S.U.; Park, J.Y.; Ahn, S.H.;
et al. Trans-arterial radioembolization versus concurrent chemoradiation therapy for locally advanced
hepatocellular carcinoma: A propensity score matching analysis. Int. J. Radiat. Oncol. 2017, 99, 396–406.
[CrossRef]
18. Spina, J.C.; Hume, I.; Pelaez, A.; Peralta, O.; Quadrelli, M.; Garcia Monaco, R. Expected and unexpected
imaging findings after 90Y trans-arterial radioembolization for liver tumors. Radiographics 2019, 39, 578–595.
[CrossRef]
Curr. Oncol. 2021, 28 976
19. Lencioni, R.; Llovet, J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin.
Liver Dis. 2010, 30, 52–60. [CrossRef]
20. Kim, B.K.; Kim, S.U.; Kim, M.J.; Kim, K.A.; Kim, D.Y.; Park, J.Y.; Ahn, S.H.; Han, K.H.; Chon, C.Y. Number of
target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with
chemoembolization. Clin. Cancer Res. 2013, 19, 1503–1511. [CrossRef]
21. Kim, B.K.; Kim, S.U.; Kim, K.A.; Chung, Y.E.; Kim, M.J.; Park, M.S.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.;
Kim, M.D.; et al. Complete response at first chemoembolization is still the most robust predictor for favorable
outcome in hepatocellular carcinoma. J. Hepatol. 2015, 62, 1304–1310. [CrossRef] [PubMed]
22. Jeon, M.Y.; Lee, H.W.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Han, K.H.; Baek, S.E.; Kim, H.S.;
Kim, S.U.; et al. Reproducibility of european association for the study of the liver criteria and modified
response evaluation criteria in solid tumors in patients treated with sorafenib. Liver Int. 2018, 38, 1655–1663.
[CrossRef]
23. Kim, B.K.; Kim, K.A.; Park, J.Y.; Ahn, S.H.; Chon, C.Y.; Han, K.H.; Kim, S.U.; Kim, M.J. Prospective comparison
of prognostic values of modified response evaluation criteria in solid tumours with european association for
the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur. J. Cancer 2013,
49, 826–834. [CrossRef]
24. Gabr, A.; Abouchaleh, N.; Ali, R.; Baker, T.; Caicedo, J.; Katariya, N.; Abecassis, M.; Riaz, A.; Lewandowski, R.J.;
Salem, R. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J. Vasc. Interv.
Radiol. 2018, 29, 1502–1510. [CrossRef] [PubMed]
25. 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 2015,
9, 267–317. [CrossRef]
26. Salem, R.; Thurston, K.G. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy
treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.
J. Vasc.Interv. Radiol. 2006, 17, 1251–1278. [CrossRef] [PubMed]
27. Singh, P.; Anil, G. Yttrium-90 radioembolization of liver tumors: What do the images tell us? Cancer Imaging
2014, 13, 645–657. [CrossRef]
28. Weng, Z.; Ertle, J.; Zheng, S.; Lauenstein, T.; Mueller, S.; Bockisch, A.; Gerken, G.; Yang, D.; Schlaak, J.F. A new
model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.
PLoS ONE 2013, 8, e82225. [CrossRef] [PubMed]
29. Gordic, S.; Corcuera-Solano, I.; Stueck, A.; Besa, C.; Argiriadi, P.; Guniganti, P.; King, M.; Kihira, S.; Babb, J.;
Thung, S.; et al. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response
criteria versus explant pathology. J. Hepatol. 2017, 67, 1213–1221. [CrossRef]
30. Jreige, M.; Mitsakis, P.; Van Der Gucht, A.; Pomoni, A.; Silva-Monteiro, M.; Gnesin, S.; Boubaker, A.;
Nicod-Lalonde, M.; Duran, R.; Prior, J.O.; et al. 18F-FDG PET/CT predicts survival after 90Y trans-arterial
radioembolization in unresectable hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2017, 44,
1215–1222. [CrossRef]
31. Riaz, A.; Kulik, L.; Lewandowski, R.J.; Ryu, R.K.; Giakoumis Spear, G.; Mulcahy, M.F.; Abecassis, M.; Baker, T.;
Gates, V.; Nayar, R.; et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal
radiation using yttrium-90 microspheres. Hepatology 2009, 49, 1185–1193. [CrossRef] [PubMed]
32. Labgaa, I.; Tabrizian, P.; Titano, J.; Kim, E.; Thung, S.N.; Florman, S.; Schwartz, M.; Melloul, E. Feasibility
and safety of liver transplantation or resection after trans-arterial radioembolization with Yttrium-90 for
unresectable hepatocellular carcinoma. HPB 2019, 10, 1497–1504. [CrossRef]
33. Jeong, S.O.; Kim, E.B.; Jeong, S.W.; Jang, J.Y.; Lee, S.H.; Kim, S.G.; Cha, S.W.; Kim, Y.S.; Cho, Y.D.; Kim, H.S.;
et al. Predictive factors for complete response and recurrence after trans-arterial chemoembolization in
hepatocellular carcinoma. Gut Liver 2017, 11, 409–416. [CrossRef]
34. Vesselle, G.; Quirier-Leleu, C.; Velasco, S.; Charier, F.; Silvain, C.; Boucebci, S.; Ingrand, P.; Tasu, J.P. Predictive
factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular
carcinoma. Eur. Radiol. 2016, 26, 1640–1648. [CrossRef] [PubMed]
35. Park, Y.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Han, K.H.; Yeon, J.E.; Byun, K.S.; Kim, H.S.; Kim, J.H.; et al.
Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for
hepatocellular carcinoma. BMC Cancer 2019, 19, 363. [CrossRef] [PubMed]
Curr. Oncol. 2021, 28 977
36. Kamath, P.S.; Wiesner, R.H.; Malinchoc, M.; Kremers, W.; Therneau, T.M.; Kosberg, C.L.; D’Amico, G.;
Dickson, E.R.; Kim, W.R. A model to predict survival in patients with end-stage liver disease. Hepatology
2001, 33, 464–470. [CrossRef]
37. Mazzaferro, V.; Sposito, C.; Bhoori, S.; Romito, R.; Chiesa, C.; Morosi, C.; Maccauro, M.; Marchiano, A.;
Bongini, M.; Lanocita, R.; et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular
carcinoma: A phase 2 study. Hepatology 2013, 57, 1826–1837. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
